Advances in the use of multimarker panels for renal risk stratification

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 3, 2012, Pages 301-308

  Weekley, Cristin C ^a,b   Peralta, Carmen A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

albuminuria; chronic kidney disease; creatinine; cystatin C; multimarker

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; CYSTATIN C; FIBRINOGEN; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN;

ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DEATH; DISEASE CLASSIFICATION; DISEASE COURSE; FIBRINOGEN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY FAILURE; MICROALBUMINURIA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84859627662     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328352132d     Document Type: Review

References (31)

1. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004; 23:1631-1660.
2. Kleinman LC, Norton EC. What's the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res 2009; 44:288-302.
3. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-470.
4. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829.
5. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172; discussion 207-212.
6. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150:795-802. This article illustrates the principle of estimating and interpreting reclassification improvement methods.
7. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.
8. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612.
9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113:S1-S130.
11. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081. This study represents the largest investigation showing that eGFR and albuminuria are independent and complementary predictors of death.
12. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303:423-429.
13. Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17:1444-1452.
14. Tonelli M, Jose P, Curhan G, et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332:1426.
15. Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA 2004; 291:844-850.
16. Fox CS, Gona P, Larson MG, et al. A multimarker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 2010; 21:2143-2149. This article explores several novel circulation biomarkers that may aid in predicting incident CKD and microalbuminuria.
17. Shastri S, Katz R, Shlipak MG, et al. Cystatin C and albuminuria as risk factors for development of CKD stage 3: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2011; 57:832-840.
18. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22:147-155. This article assessed the use of cystatin C for identification of persons with CKD that were missed by creatinine, and who have high risk for adverse events. Among adults diagnosed with CKD using the creatinine-based Chronic Kidney Disease EpidemiologyCollaboration (CKD-EPI) equation, the adverse prognosis is limited to the subset who also have CKD according to the cystatin C-based equation.
19. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352:2049-2060.
20. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
21. Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3418 individuals with CKD. Am J Kidney Dis 2008; 51:395-406.
22. Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305:1545-1552. This article evaluates using the combination of creatinine, cystatin C, and albuminuria to improve detection and risk stratification for death, heart failure, cardiovascular events, and ESRD compared with creatinine alone.
23. Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005; 25:135-143.
24. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. Jama 2011; 305:1553-1559. The authors developed a highly accurate individual risk score to predict progression to ESRD using readily available clinical markers.
25. Astor BC, Kottgen A, Hwang SJ, et al. Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol 2011; 34:291-297.
26. O'Seaghdha CM, Hwang SJ, Bhavsar NA, et al. Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population. Am J Kidney Dis 2011; 57:841-849.
27. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:337-344.
28. Boger CA, Chen MH, Tin A, et al. CUBN is a gene locus for albuminuria. J Am Soc Nephrol 2011; 22:555-570.
29. Liu CT, Garnaas MK, Tin A, et al. Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet 2011; 7:e1002264.
30. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-845. This is a seminal article identifying a genetic variant strongly associated with kidney disease in African-Americans.
31. Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009; 150:65-72.